INBX Stock: Why It Substantially Increased Today

By Amit Chowdhry ● Oct 12, 2021
  • The stock price of Inhibrx Inc (NASDAQ: INBX) increased by over 21% during intraday trading. This is why it happened.

The stock price of Inhibrx Inc (NASDAQ: INBX) – a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline – increased by over 21% during intraday trading. Investors are responding positively to Inhibrx announcing interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD.

The interim functional PK data from this multi-country multi-center Phase 1 study are from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene, the underlying cause of AATD. Interim safety data are from 24 patients with AATD. And there were no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose.

The drug-related adverse events were predominantly mild with a few moderate events and all were transient and reversible. And no signs of neutralizing anti-drug antibodies have been seen.

The dose related increases in maximal and total INBRX-101 exposure occurred across the entirety of the tested single ascending dose range of 10 to 120 mg/kg. And data from the first multiple ascending dose cohort of INBRX-101 at 40 mg/kg IV every 3 weeks showed the expected accumulation of functional alpha-1 antitrypsin, or AAT, levels with observed trough levels exceeding the goal of the current standard augmentation therapy with plasma-derived AAT.

The functional AAT and bronchoalveolar lavage data from patients to be administered three INBRX-101 doses of 80 or 120 mg/kg IV every 3 weeks are expected in the first half of 2022.

KEY QUOTE:

“These initial data demonstrate the potential of INBRX-101 to significantly improve treatment for patients with AATD by maintaining them in the normal range of functional AAT and reducing infusions from 52 annually to possibly as few as 12 annually.”

— Mark Lappe, CEO of Inhibrx

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.